Timothy Hart, MD
Family Medicine · Catlettsburg, KYNPI 1174668420
Payments from drug & device makers
Across 728 payments — averaging $13.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- AstraZeneca$911
- Lilly USA, LLC$675
- Pfizer$644
- Johnson & Johnson$530
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,612100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 159 | $1,773 |
| Novo Nordisk | 145 | $1,647 |
| AstraZeneca | 43 | $911 |
| Lilly USA, LLC | 43 | $675 |
| Pfizer | 53 | $644 |
| Johnson & Johnson | 39 | $530 |
| Bayer | 26 | $455 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 24 | $381 |
| Merck | 32 | $372 |
| Amarin Pharma, Inc. | 26 | $286 |
| Otsuka America Pharmaceutical, Inc. | 18 | $278 |
| Novartis | 18 | $260 |
| Esperion Therapeutics, Inc. | 19 | $239 |
| Kowa Pharmaceuticals America, Inc. | 15 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $163 |
| Boehringer Ingelheim | 6 | $89 |
| Abbott | 6 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $87 |
| Amgen | 4 | $63 |
| Almatica Pharma LLC | 4 | $57 |
| Lundbeck LLC | 3 | $45 |
| Eisai Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| Alkermes, Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 3 | $36 |
| GSK | 2 | $33 |
| Shire North American Group Inc | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Abiomed | 1 | $16 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
| Shionogi Inc | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,634 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 169 | $249,011 |
| EliquisApixaban | 280 | $166,363 |
| FarxigaDapagliflozin Propanediol | 110 | $120,919 |
| TrulicityDulaglutide | 109 | $105,162 |
| JardianceEmpagliflozin | 70 | $81,601 |
| JanuviaSitagliptin Phosphate | 79 | $71,468 |
| MounjaroTirzepatide | 64 | $68,467 |
| LinzessLinaclotide | 92 | $59,727 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $57,997 |
| XareltoRivaroxaban | 44 | $46,146 |
| RybelsusSemaglutide | 25 | $25,363 |
| MyrbetriqMirabegron | 66 | $22,142 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $21,932 |
| GemtesaVibegron | 54 | $21,208 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $17,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,647 | $274,373194 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $675 | $173,628173 claims |
| PfizerEliquis, Abrysvo | $644 | $172,054299 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $911 | $142,851139 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix, Arexvy | $33 | $94,747161 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $89 | $92,81892 claims |
| MerckJanuvia | $372 | $71,46879 claims |
| AbbVieLinzess | $1,773 | $59,72792 claims |
| Johnson & JohnsonXarelto | $530 | $46,14644 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $278 | $13,55011 claims |
| BayerKerendia | $455 | $9,97012 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $214 | $8,37916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Catlettsburg
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.